Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation

Trial Profile

Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Non-radiographic axial spondyloarthritis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms C-AXSPAND
  • Sponsors UCB; UCB Biosciences
  • Most Recent Events

    • 14 Nov 2022 Results of post hoc analysis assessing baseline MRI and CRP status impacted long-term (3-year) clinical responses to certolizumab pegol, presented at the ACR Convergence 2022.
    • 04 Jun 2022 Results of post hoc analysis evaluating whether patients baseline MRI and CRP status impacted long-term (3-year) clinical responses to CZP, presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 09 Nov 2021 Results presented at the ACR Convergence 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top